Advertisement

Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure

  • Persio David Lopez
    Affiliations
    Department of Cardiology, James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York

    Mount Sinai Heart, Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Kirtipal Bhatia
    Affiliations
    Department of Cardiology, James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York

    Mount Sinai Heart, Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Chandrashekar Bohra
    Affiliations
    Department of Cardiology, James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York

    Mount Sinai Heart, Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Kiran Mahmood
    Affiliations
    Mount Sinai Heart, Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai, New York, New York

    Mount Sinai Heart, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Lawrence Baruch
    Affiliations
    Department of Cardiology, James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York

    Mount Sinai Heart, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Calvin Eng
    Correspondence
    Corresponding author: Tel: 718-584-9000; Fax: 718-741-4295.
    Affiliations
    Department of Cardiology, James J. Peters Department of Veterans Affairs Medical Center, Bronx, New York

    Mount Sinai Heart, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
      Sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce the risk of cardiovascular events and heart failure hospitalization (HFH) in patients with heart failure with reduced ejection fraction (HFrEF), diabetes mellitus type 2 (DM2), and atherosclerotic cardiovascular disease (ASCVD). The role of glucagon-like peptide 1 agonists (GLP1a) in these patients is unclear. We designed this study to assess if the addition of GLP1a to SGLT2i therapy improves outcomes in patients with HFrEF, DM2, and ASCVD. This was a retrospective cohort study of patients with DM2, ASCVD, and HFrEF in the national Veterans Affairs database. Patients on SGLT2i were propensity matched to patients on both SGTL2i and GLP1a. The co-primary outcomes were HFH and the composite of all-cause death, myocardial infarction, and stroke. We assessed them through a Cox regression model including unbalanced baseline characteristics. From a cohort of 5,576 patients, 343 were propensity matched to each study arm. The addition of GLP1a was associated with a 67% reduction in the 1-year risk of a composite event compared with therapy with SGLT2i (confidence interval 0.138 to 0.714, p = 0.007). The risk of HFH was not significantly different between both arms (p = 0.199). Sensitivity analyses in the unmatched dataset confirmed these findings. In conclusion, the addition of GLP1a to SGLT2i may reduce the risk of adverse events in patients with HFrEF who have DM2 and ASCVD, but it does not affect the risk of HFH.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Reference

        • Virani SS
        • Alonso A
        • Aparicio HJ
        • Benjamin EJ
        • Bittencourt MS
        • Callaway CW
        • Carson AP
        • Chamberlain AM
        • Cheng S
        • Delling FN
        • Elkind MSV
        • Evenson KR
        • Ferguson JF
        • Gupta DK
        • Khan SS
        • Kissela BM
        • Knutson KL
        • Lee CD
        • Lewis TT
        • Liu J
        • Loop MS
        • Lutsey PL
        • Ma J
        • Mackey J
        • Martin SS
        • Matchar DB
        • Mussolino ME
        • Navaneethan SD
        • Perak AM
        • Roth GA
        • Samad Z
        • Satou GM
        • Schroeder EB
        • Shah SH
        • Shay CM
        • Stokes A
        • VanWagner LB
        • Wang NY
        • Tsao CW
        American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke Statistics-2021 update: a report From the American Heart Association.
        Circulation. 2021; 143: e254-e743
        • Goderis G
        • Vaes B
        • Mamouris P
        • van Craeyveld E
        • Mathieu C.
        Prevalence of atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in patients with type 2 diabetes mellitus: a primary care research network-based study.
        Exp Clin Endocrinol Diabetes. 2022; 130: 447-453
        • Zelniker TA
        • Wiviott SD
        • Raz I
        • Im K
        • Goodrich EL
        • Furtado RHM
        • Bonaca MP
        • Mosenzon O
        • Kato ET
        • Cahn A
        • Bhatt DL
        • Leiter LA
        • McGuire DK
        • Wilding JPH
        • Sabatine MS.
        Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus.
        Circulation. 2019; 139: 2022-2031
        • Cosentino F
        • Grant PJ
        • Aboyans V
        • Bailey CJ
        • Ceriello A
        • Delgado V
        • Federici M
        • Filippatos G
        • Grobbee DE
        • Hansen TB
        • Huikuri HV
        • Johansson I
        • Jüni P
        • Lettino M
        • Marx N
        • Mellbin LG
        • Östgren CJ
        • Rocca B
        • Roffi M
        • Sattar N
        • Seferović PM
        • Sousa-Uva M
        • Valensi P
        • Wheeler DC
        ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
        Eur Heart J. 2020; 41: 255-323
        • Das SR
        • Everett BM
        • Birtcher KK
        • Brown JM
        • Januzzi Jr, JL
        • Kalyani RR
        • Kosiborod M
        • Magwire M
        • Morris PB
        • Neumiller JJ
        • Sperling LS.
        2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology solution set oversight committee.
        J Am Coll Cardiol. 2020; 76: 1117-1145
        • American Diabetes Association. 10
        Cardiovascular disease and risk management: standards of medical care in Diabetes-2021.
        Diabetes Care. 2021; 44 (Published correction appears in Diabetes Care 2021;44:2183–2185): S125-S150
        • Tang J
        • Wan JY
        • Bailey JE.
        Performance of comorbidity measures to predict stroke and death in a community-dwelling, hypertensive Medicaid population.
        Stroke. 2008; 39: 1938-1944
        • Dominick KL
        • Dudley TK
        • Coffman CJ
        • Bosworth HB.
        Comparison of three comorbidity measures for predicting health service use in patients with osteoarthritis.
        Arthritis Rheum. 2005; 53: 666-672
        • Sharabiani MT
        • Aylin P
        • Bottle A.
        Systematic review of comorbidity indices for administrative data.
        Med Care. 2012; 50: 1109-1118
        • Yurkovich M
        • Avina-Zubieta JA
        • Thomas J
        • Gorenchtein M
        • Lacaille D.
        A systematic review identifies valid comorbidity indices derived from administrative health data.
        J Clin Epidemiol. 2015; 68: 3-14
        • Andries G
        • Yandrapalli S
        • Aronow WS.
        Benefit-risk review of different drug classes used in chronic heart failure.
        Expert Opin Drug Saf. 2019; 18: 37-49
        • Kristensen SL
        • Rørth R
        • Jhund PS
        • Docherty KF
        • Sattar N
        • Preiss D
        • Køber L
        • Petrie MC
        • McMurray JJV.
        Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet Diabetes Endocrinol. 2019; 7: 776-785
        • Scheen AJ.
        GLP-1 receptor agonists and heart failure in diabetes.
        Diabetes Metab. 2017; 43 (Suppl): 2S13-2S19
        • Goldenberg RM
        • Ahooja V
        • Clemens KK
        • Gilbert JD
        • Poddar M
        • Verma S.
        Practical considerations and rationale for glucagon-like Peptide-1 receptor agonist plus sodium-dependent glucose Cotransporter-2 inhibitor combination therapy in type 2 diabetes.
        Can J Diabetes. 2021; 45: 291-302
        • Pfeffer MA
        • Claggett B
        • Diaz R
        • Dickstein K
        • Gerstein HC
        • Køber LV
        • Lawson FC
        • Ping L
        • Wei X
        • Lewis EF
        • Maggioni AP
        • McMurray JJ
        • Probstfield JL
        • Riddle MC
        • Solomon SD
        • Tardif JC
        • Investigators ELIXA
        Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.
        N Engl J Med. 2015; 373: 2247-2257
        • Margulies KB
        • Hernandez AF
        • Redfield MM
        • Givertz MM
        • Oliveira GH
        • Cole R
        • Mann DL
        • Whellan DJ
        • Kiernan MS
        • Felker GM
        • McNulty SE
        • Anstrom KJ
        • Shah MR
        • Braunwald E
        • Cappola TP
        NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.
        JAMA. 2016; 316: 500-508
        • Marso SP
        • Daniels GH
        • Brown-Frandsen K
        • Kristensen P
        • Mann JF
        • Nauck MA
        • Nissen SE
        • Pocock S
        • Poulter NR
        • Ravn LS
        • Steinberg WM
        • Stockner M
        • Zinman B
        • Bergenstal RM
        Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322
        • Marso SP
        • Bain SC
        • Consoli A
        • Eliaschewitz FG
        • Jódar E
        • Leiter LA
        • Lingvay I
        • Rosenstock J
        • Seufert J
        • Warren ML
        • Woo V
        • Hansen O
        • Holst AG
        • Pettersson J
        • Vilsbøll T
        SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes.
        N Engl J Med. 2016; 375: 1834-1844
        • Lepore JJ
        • Olson E
        • Demopoulos L
        • Haws T
        • Fang Z
        • Barbour AM
        • Fossler M
        • Davila-Roman VG
        • Russell SD
        • Gropler RJ.
        Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction.
        JACC Heart Fail. 2016; 4: 559-566
        • Nauck MA
        • Quast DR
        • Wefers J
        • Meier JJ.
        GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
        Mol Metab. 2021; 46101102
        • Sattar N
        • Lee MMY
        • Kristensen SL
        • Branch KRH
        • Del Prato S
        • Khurmi NS
        • Lam CSP
        • Lopes RD
        • McMurray JJV
        • Pratley RE
        • Rosenstock J
        • Gerstein HC.
        Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
        Lancet Diabetes Endocrinol. 2021; 9: 653-662
        • Nauck MA
        • Meier JJ
        • Cavender MA
        • Abd El Aziz M
        • Drucker DJ
        Cardiovascular actions and clinical outcomes with glucagon-like Peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
        Circulation. 2017; 136: 849-870
        • Zhao TC.
        Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection.
        Cardiovasc Diabetol. 2013; 12: 90
        • Adamo L
        • Rocha-Resende C
        • Prabhu SD
        • Mann DL.
        Reappraising the role of inflammation in heart failure.
        Nat Rev Cardiol. 2020; 17: 269-285
        • Hartupee J
        • Mann DL.
        Neurohormonal activation in heart failure with reduced ejection fraction.
        Nat Rev Cardiol. 2017; 14: 30-38
        • Packer M
        • Anker SD
        • Butler J
        • Filippatos G
        • Pocock SJ
        • Carson P
        • Januzzi J
        • Verma S
        • Tsutsui H
        • Brueckmann M
        • Jamal W
        • Kimura K
        • Schnee J
        • Zeller C
        • Cotton D
        • Bocchi E
        • Böhm M
        • Choi DJ
        • Chopra V
        • Chuquiure E
        • Giannetti N
        • Janssens S
        • Zhang J
        • JR Gonzalez Juanatey
        • Kaul S
        • HP Brunner-La Rocca
        • Merkely B
        • Nicholls SJ
        • Perrone S
        • Pina I
        • Ponikowski P
        • Sattar N
        • Senni M
        • Seronde MF
        • Spinar J
        • Squire I
        • Taddei S
        • Wanner C
        • F; Zannad
        EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure.
        N Engl J Med. 2020; 383: 1413-1424
        • Zinman B
        • Wanner C
        • Lachin JM
        • Fitchett D
        • Bluhmki E
        • Hantel S
        • Mattheus M
        • Devins T
        • Johansen OE
        • Woerle HJ
        • Broedl UC
        • Inzucchi SE
        EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128